![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NOVO NORDISK RECEIVES APPROVAL IN THE EU FOR USE OF NOVORAPID IN PREGNANCY
NOVO NORDISK RECEIVES APPROVAL IN THE EU FOR USE OF NOVORAPID IN PREGNANCY
August 1, 2006
Novo Nordisk announced that the European Commission has approved the rapid-acting insulin NovoRapid (insulin aspart) for use by pregnant women with diabetes. The approval follows results of the largest ever randomised controlled trial of modern insulin in pregnant women with type 1 diabetes. NovoRapid is the first modern insulin that has a label stating it can be used in pregnancy in the EU.
Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5545/101/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct